CHICAGO (Reuters) - Virtually all of the experts who wrote favorably about GlaxoSmithKline Plc's troubled diabetes drug Avandia had financial ties to drug makers, a finding that shows the need for reform of such relationships, U.S. researchers said on Thursday. A team ...
WASHINGTON (Reuters) - U.S. regulators, drug companies, philanthropists and advocates announced a new alliance on Thursday to speed tuberculosis drugs to market, a day after cancer researchers and drugmakers launched a similar initiative. The U.S. Food and Drug Administration said it will ...
AstraZeneca PLC's blockbuster psychiatric drug Seroquel did not trigger diabetes in a Vietnam veteran, a jury ruled Thursday in the first trial out of thousands of cases alleging the powerful drug caused diabetes. The British drugmaker said a jury in Middlesex County ...
WASHINGTON (Reuters) - Novartis AG and Astellas Pharma eczema drugs may need their warning labels expanded after dozens of new reported cases of cancer and infection in children, U.S. Food and Drug Administration staff said in documents released on Thursday. Agency scientists ...
LONDON (Reuters) - It's been a bad month for Pfizer's <PFE.N> research labs but its head of R&D says the world's biggest drugmaker is on track to hit earlier targets for new drug filings despite the setbacks. "We have had some disappointments, ...
NEW YORK/LONDON (Reuters) - AstraZeneca Plc <AZN.L> won a U.S. court battle on Thursday over product liability claims for its blockbuster Seroquel schizophrenia treatment, the first such case to go to trial. Thousands of plaintiffs have filed lawsuits claiming that Seroquel caused ...
In this undated product image released by AstraZaneca, Seroquel tablets are shown. AstraZeneca on Thursday, March 18, 2010 said a jury in Middlesex County Superior Court in New Jersey ruled in favor of the British drugmaker in the first trial brought by ...
Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH — in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion. Teva Pharmaceutical Industries Ltd.'s successful bid will give it ...
Israeli pharma giant Teva said on Thursday it had signed a deal to buy Ratiopharm, Germany's second largest generic drugs producer, for 3.6 billion euros (4.9 billion dollars). "The acquisition will position Teva as the leading generic pharmaceutical company in Europe," the ...
FILE - Dec. 2, 2008 file photo shows the the company name and logo of generic medicine company Ratiopharm] on a building of the headquarters in Ulm, southern Germany. Israeli drug maker Teva said Thursday, March 18, 2010 it has beat out ...
